News & Events
Press Releases
September 6, 2023
September 06, 2023
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
March 20, 2023
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting
February 08, 2023
Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary
December 13, 2022
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
November 30, 2022
Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis
October 26, 2022
Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer
October 11, 2022
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK
September 12, 2022
Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
August 24, 2022
Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting
May 19, 2022
Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting
April 13, 2022
Nimbus Therapeutics Strengthens Clinical Development Leadership Team
April 08, 2022
Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting
March 28, 2022
Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting
March 25, 2022
Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting
February 03, 2022
Nimbus Therapeutics Shares Update on Discovery Efforts in Computational Chemistry, Expands Leadership Team
January 06, 2022
Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor Program and Provides Additional Business Updates
November 12, 2021
Nimbus Therapeutics Announces First Patient Dosed in Phase 1/2 Study of a Highly Selective HPK1 Inhibitor in Patients with Solid Tumors
September 30, 2021
Nimbus Therapeutics Publishes Structural Analysis Highlighting Mechanisms for Selective Inhibition of CTPS1
September 21, 2021
Nimbus Therapeutics Appoints Ian Sanderson, MBA, as Chief Financial Officer
September 14, 2021
Nimbus Therapeutics Announces First Patient Dosed in Phase 2b Study of Oral Allosteric TYK2 Inhibitor in Patients with Moderate to Severe Psoriasis
August 12, 2021
Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets
July 13, 2021
Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs
May 10, 2021
Nimbus Therapeutics Appoints Anne McGeorge to its Board of Directors
April 21, 2021
Nimbus Therapeutics Expands Development Team to Advance Multiple Portfolio Programs Through Clinical Testing
April 09, 2021
Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor
December 30, 2020
Nimbus Therapeutics Regains Worldwide Rights to HPK1 Inhibitor Program from Bristol Myers Squibb
November 05, 2020
Nimbus Therapeutics to Present Updated Preclinical Data From HPK1 Inhibitor Program in Scientific Seminar
October 22, 2020
Nimbus Therapeutics to Present New Data on Novel HPK1 Inhibitors at Upcoming Scientific Conferences
October 19, 2020
Nimbus Therapeutics Appoints Erin Cowhig as Chief People Officer
October 14, 2020
Nimbus Therapeutics Announces $60 Million Private Financing From New Investors to Advance Expanded Pipeline
September 28, 2020
Nimbus Therapeutics Appoints Abbas Kazimi as Chief Business Officer
September 01, 2020
Nimbus Therapeutics Appoints Veteran Pharmaceutical Chemist Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry
June 22, 2020
Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo
June 18, 2020
Nimbus Therapeutics to Host Scientific Seminar on Promising Preclinical Data from HPK1 Program
June 08, 2020
Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism
May 29, 2020
Nimbus Therapeutics Announces Promotion of Alan Collis, Ph.D., to Senior Vice President, Preclinical Development
May 15, 2020
Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity
December 17, 2019
Nimbus Therapeutics Appoints Chief Medical Officer Annie C. Chen, M.D., MPH, to President of the Company’s Tyk2 Subsidiary
September 19, 2019
Nimbus Therapeutics Appoints Accomplished Biologist and Research Director Christine Loh, Ph.D., to Lead Biology Team
July 09, 2019
Nimbus Therapeutics and Celgene Expand Alliance to Immunotherapy in Oncology
April 03, 2019
Nimbus Therapeutics Publishes First-Ever High-Resolution Structure of ATP-Citrate Lyase
March 20, 2019
Nimbus Therapeutics Grows Scientific Team, Adding Leaders in Biology and Preclinical Development
February 14, 2019
Nimbus Therapeutics Appoints Peter Tummino, Ph.D., as Chief Scientific Officer
January 03, 2019
Nimbus Therapeutics Strengthens Leadership Team
October 04, 2018
Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer
July 09, 2018
Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology
June 05, 2018
Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts
March 08, 2018
Nimbus Therapeutics Announces Departure of Chief Scientific Officer Rosana Kapeller, M.D., Ph.D.
October 03, 2017
Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance to Develop Programs for Patients with Autoimmune Disorders
April 05, 2017
Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories to Advance New Therapeutics Programs
January 05, 2017
Nimbus Therapeutics Appoints Mark Ashwell, Ph.D., as Head of Chemistry
November 01, 2016
Nimbus Therapeutics announces $200 million milestone payment from Gilead Sciences for Allosteric ACC Inhibitor program in Non-alcoholic steatohepatitis (NASH)
September 19, 2016
Nimbus Therapeutics’ ACC Inhibitor Nd-646 Featured in Nature Medicine
May 17, 2016
Nimbus Therapeutics Announces Closing of Gilead Sciences’ Acquisition of Nimbus Apollo, Inc., and Its Acetyl-Coa Carboxylase (ACC) Inhibitor Program
April 04, 2016
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-Coa Carboxylase (ACC) Program for Nash and Other Liver Diseases
February 02, 2016
Nimbus Therapeutics Granted Fast Track Designation for Its Allosteric ACC Inhibitor, Ndi-010976, for the Treatment of Nash
December 22, 2015
Nimbus Therapeutics Achieves Second Milestone in Research Collaboration with Monsanto
November 10, 2015
Nimbus Therapeutics Announces Progress On Key Therapeutic Programs
October 20, 2015
Nimbus Therapeutics Announces Global License Agreement with Genentech
September 09, 2015
Nimbus Therapeutics Appoints Annie C Chen, M.D., M.P.H., as Chief Medical Officer
July 07, 2015
Nimbus Therapeutics Appoints Mark Iwicki and George Vlasuk to Its Board of Directors
April 21, 2015
Nimbus Therapeutics Announces Initiation of Clinical Studies For ACC Inhibitor
March 18, 2015
Nimbus Therapeutics Raises $43 Million in Series B Financing
December 10, 2014
First Milestone Reached in Monsanto Collaboration
November 04, 2014
Jeb Keiper, M.S., M.B.A., Appointed Nimbus Discovery CBO
September 30, 2014
Donald Nicholson, Ph.D., Appointed Nimbus Discovery CEO
April 01, 2014
Selective ACC Inhibitors Dramatically Impact Tumor Growth
December 09, 2013
IRAK4 Inhibitor Demonstrates Synergistic Effects with Kinase Inhibitors
November 04, 2013
ACC Inhibitors for Potential Diabetes, Nash and Liver Cancer Treatment
June 27, 2013
Nimbus Discovery and Monsanto Announce Collaboration
June 22, 2013
Preclinical Proof of Concept Data on Novel ACC Allosteric Inhibitor Nd-630
May 08, 2013
Nimbus and Shire To Co-Develop Therapies for Rare Diseases
February 06, 2013
Wes Westlin Appointed Head of Preclinical Research and Early Development
January 28, 2013
Inhibitors for Treatment of Metabolic Syndrome and Diabetes
December 09, 2012
Irak4 Inhibitors Synergize with Ibrutinib
November 12, 2012
Irak4 Inhibitors for the Treatment of Rheumatic Diseases
November 08, 2012
Nimbus-Proteros X-Ray Crystallography Partnership
November 01, 2012
Daniel Lynch Joins Nimbus As Executive Chairman
April 20, 2012
2012 Women to Watch: Rosana Kapeller
April 19, 2012
Cycle Computing Ramps Global 50,000-Core Cluster For Schrodinger Molecular Research
June 28, 2011
Nimbus Discovery Secures $24mm Series A Financing
March 10, 2011
Nimbus Discovery Unveils First of Its Kind Drug Discovery Paradigm; Announces Seed Round Co-Led By Bill Gates
In the News
March 18, 2023
Bloomberg Business
February 21, 2023
Boston Globe Magazine
December 16, 2022
BioPharma Dive
December 13, 2022
Endpoints
Our Perspectives
Latest Story
The Book of Nimbus
April 27, 2023
The Book of Nimbus is still being written, but its arc over the years already shows the shape of what I believe to be Nimbus’ mark on our industry: as an R&D powerhouse with the potential to repeatedly create breakthrough medicines for patients.
Latest Story
The Book of Nimbus
April 27, 2023
The Book of Nimbus is still being written, but its arc over the years already shows the shape of what I believe to be Nimbus’ mark on our industry: as an R&D powerhouse with the potential to repeatedly create breakthrough medicines for patients.
Latest Story
Core (Values) Workout
March 05, 2020
Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done: run. Injury stopped me from running last fall and I’ve since seen orthopods and running experts galore.
But it’s been the physical therapists who’ve really laid the hammer home: “Jeb, you need to work on your core.”
Latest Story
Latest Story
Recent Stories
Recent Stories
Recent Stories
Recent Stories
Upcoming Events
Royal Society of Chemistry 22nd Medicinal Chemistry Symposium
We look forward to presenting at the Royal Society of Chemistry 22nd Medicinal Chemistry Symposium in Cambridge, UK.
September 10-13, 2023
Discovery on Target
Nimbus will present at the 20th Annual Discovery on Target Conference in Boston, MA.
September 25-28, 2023
Fierce Biotech Summit
Nimbus CBO Abbas Kazimi will speak on the panel ‘The Future of M&A, Licensing Deals and Partnerships’ at the 2023 Fierce Biotech Summit.
October 16-18, 2023
